Morgan Stanley Sorrento Therapeutics, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.74 - $1.83 $56,345 - $139,339	-76,142 Reduced 6.93%	1,022,825 $910,000
Q3 2022 Nov 14, 2022	SELL	$1.51 - $2.88 $2.83 Million - $5.39 Million	-1,873,064 Reduced 63.02%	1,098,967 $1.73 Million
Q2 2022 Oct 27, 2022	SELL	$1.24 - $2.33 $383,386 - $720,396	-309,183 Reduced 9.42%	2,972,031 $5.97 Million
Q2 2022 Aug 15, 2022	SELL	$1.24 - $2.33 $383,386 - $720,396	-309,183 Reduced 9.42%	2,972,031 $5.97 Million
Q1 2022 Oct 27, 2022	BUY	$2.0 - $4.9 $618,366 - $1.51 Million	309,183 Added 10.4%	3,281,214 $7.65 Million
Q1 2022 May 13, 2022	BUY	$2.0 - $4.9 $4.74 Million - $11.6 Million	2,367,713 Added 259.19%	3,281,214 $7.65 Million
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.23 $242,878 - $377,637	52,232 Added 6.06%	913,501 $4.25 Million
Q3 2021 Nov 15, 2021	BUY	$7.41 - $10.99 $6.38 Million - $9.47 Million	861,269 New	861,269 $6.57 Million

5.47M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.